mci 9038 has been researched along with Obesity in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Medico, CJ; Walsh, P | 1 |
| Baillie, GM; Hursting, MJ; McCollum, DA; Rice, L | 1 |
| Hursting, MJ; Jang, IK | 1 |
1 review(s) available for mci 9038 and Obesity
| Article | Year |
|---|---|
Pharmacotherapy in the critically ill obese patient.
Topics: Aminoglycosides; Antithrombins; Arginine; Body Mass Index; Carbapenems; Cephalosporins; Drug Dosage Calculations; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Hypnotics and Sedatives; Lipopeptides; Obesity; Oxazolidinones; Penicillins; Pipecolic Acids; Protein C; Quinolones; Recombinant Proteins; Safety; Sulfonamides; Vancomycin | 2010 |
2 other study(ies) available for mci 9038 and Obesity
| Article | Year |
|---|---|
Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia.
Topics: Anticoagulants; Arginine; Body Weight; Female; Heparin; Humans; Male; Obesity; Partial Thromboplastin Time; Pipecolic Acids; Platelet Count; Retrospective Studies; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2007 |
Effect of body mass index on Argatroban therapy during percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Blood Coagulation; Body Mass Index; Coronary Artery Disease; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Obesity; Pipecolic Acids; Retrospective Studies; Sulfonamides; Thrombocytopenia | 2008 |